WORLD'S FIRST DEDICATED MEDITATION COURSE FOR THE LGBTQ+ COMMUNITY

World's First LGBTQ+ Meditation Courses

World’s First LGBTQ+ Meditation Courses

LGBTQ+ Meditation Courses - crafted by the LGBTQ+ Community

LGBTQ+ Meditation Courses – crafted by the LGBTQ+ Community

FISU Meditation Academy

FISU Meditation Academy

We have crafted the world's first LGBTQ+ Meditation Course beginning on Sunday, 31st January 2021 at 2 PM GMT / 9 AM EST.

LONDON, UNITED KINGDOM, January 19, 2021 /EINPresswire.com/ — WORLD'S FIRST DEDICATED MEDITATION COURSE FOR THE LGBTQ+ COMMUNITY

We have crafted the world's first LGBTQ+ Meditation Course beginning on Sunday, 31st January 2021 at 2 PM GMT / 9 AM EST.

This 12 week course is built on our LGBTQ+ community meditators' profound and life changing experiences. Some of them are now teachers on this project to help spread the profound and life-transforming benefits of meditation to the LGBTQ+ community.

A perfect lockdown antidote!

There are many single meditation lessons and videos around the web for the community. Still, none are dedicated to taking you in a personal journey of self-discovery and strengthening over 12 weeks led by an LGBTQ+ instructor.

Ten live instructor-led sessions are delivered through our innovative course player integrated with Zoom, plus 45 self-paced study lessons via videos, audios and eBooks. The self-paced study lessons follow the course's path and deliver content relevant to the learner's experiences at this time.

Online Course Details and schedule: https://academy.fisu.org/course/lgbtq-meditation-course

Here are some of the many course benefits (an expanded version is on the site here: https://academy.fisu.org/course/lgbtq-meditation-course)
• Coming Out – Gain strength to make it a celebration of your identity
• Self Acceptance & Loving Yourself
• Calm, Relaxation & Peace of Mind – Stop Mind Chatter
• Improve Mental Health Well-Being especially through lockdown
• Overcoming Depression – Meditation is more effective than medication
• Dealing with and accepting those who are homophobic or transphobic and Bullying
• How to deal with negative people and their opinions
• Cultivate Compassion & Forgiveness
• Be who you want to be – Gender does not define you
• Greater Self-Esteem and Confidence
• Sharpen Concentration and accelerate Cognition
• Scene Influences – easier to steer away from "scene" influences
• How to avoid Addictions, Promiscuity, and Dependencies

All these subjects are covered within the course plus many others.

Testimonials from the LGBTQ+ Community are here: https://academy.fisu.org/course/lgbtq-meditation-course (scroll down to testimonial area).

Our Great Value Course Pricing:
The entire 12-week course cost is a reasonable GB £199/Euro €230/USD $260 – with concessions for unemployed.

Course Sessions take place on Sundays at 2 PM GMT / 9 AM EST

75 Minute Free Introductory Talks (obligatory to attend before enrolling) are regularly scheduled.

Languages: Future Courses will be taught in English, Spanish or Greek.

FISU Meditation is a non-profit organisation and registered educational charity that teaches the art of Meditation and Spiritual Unfoldment. UK Charity No:
1061185.

FISU does not have any employees worldwide, and it's teachers dedicate their time to help others as meditation has changed their lives and they want to help others change theirs.

FISU Meditation is lead by Guru Rajesh Ananda.
For more details, please contact:

FISU Meditation HQ, Marlborough Road, London, E4 9AL
Phone: Guru Rajesh Ananda Mobile: +447793 562103
Email: Rajesh.Ananda@fisu.org
Academy Online: academy.fisu.org
Main Website: www.fisu.org
Philosophy Life-Skills Website: www.gururajananda.org
Facebook: www.facebook.com/fisumeditation
Twitter: @rajeshananda
Instagram: @themeditation.guru
Platform: FISU's global operations run on the Salesforce.org platform, where it was the first meditation school to adopt the platform. The FISU Meditation Academy is integrated with Salesforce.

Rajesh Ananda
FISU Meditation
+44 7793 562103
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

iWave's New Game-Changing Multi-Lens Scoring Elevates Fundraising Customization To New Heights

iWave #1 Fundraising Solution For Nonprofits

iWave Fundraising Solutions For Nonprofits

iWave's Industry First Multi-Lens Scoring revolutionizes how nonprofits can view their donors from completely different perspectives for even more customization

CHARLOTTETOWNE, PRINCE EDWARD ISLAND, CANADA, January 19, 2021 /EINPresswire.com/ — iWave, the industry’s top-rated fundraising intelligence solution, announced today the availability of its newest feature, Multi-Lens Scoring. This revolutionary feature has never been seen before in the nonprofit industry and it furthers iWave’s leadership in the fundraising intelligence space. With it, nonprofits can easily and quickly view their donors from completely different perspectives to help them maximize fundraising goals.

Our industry-first fundraising feature elevates customization to new heights
Nonprofit organizations can fully customize their fundraising experience in iWave based on their unique donors, missions, and goals. To understand how valuable this new feature can be, it’s important to know how iWave scores prospects. iWave is the only solution that uses affinity scores to provide a holistic view of a donor. We believe a donor’s giving interest is crucial to knowing how they will give to you. iWave’s customizable scoring preferences for capacity, propensity and affinity provide the foundation for Multi-Lens Scoring. With this new feature, you can now customize your searches based on even more personal data for a complete, well-rounded donor search.

You can use Multi-Lens Scoring to:
● Find your TOP prospects who care about your mission
● Sort and cultivate donors into groups that help you reach your GOALS, faster
● Cut your research time by seeing MORE information in a comprehensive way
● Find donors in places you’ve NEVER looked before
● Be ahead of the curve and ready to ADAPT to any organization or campaign changes

Using affinity to your fullest advantage – a new perspective
As an example, a hospital may have a capital campaign to raise funds for an Arts Therapy Facility. Within iWave’s settings, the hospital is able to select Healthcare as the primary affinity (giving interest) to find donors that have donated to healthcare organizations in the past and have a high capacity and history of giving. Thanks to Multi-Lens Scoring, the customization doesn’t stop here.

Now the hospital can set up another lens by selecting Arts and Culture as the primary affinity. Under this view, they will uncover prospects that have a track record of donating to arts and culture causes or those who are an executive or a board member at an arts and culture organization.

Then they can segment top prospects into two lists based on their affinity and look at them side-by-side. The fundraising team can then engage with each group using tailored messaging that focuses on their giving interest in either healthcare or arts and culture.

“Multi-lens screening makes it possible to change the results of your data set depending on the precise propensity, affinity, and giving capacity your organization needs to support each team and each project. From annual fund to membership to major and principal giving, multi-lens screening pinpoints the prospects you should reach out to now. I cannot wait to work with our clients to help them take advantage of this powerful new feature,” said Erin Lynch Moran, Partner, The Solas Group.

Change the game with 5 unique lenses
Ultimately, this innovative new feature means even more customization for your fundraising efforts. With 5 lenses to try, fundraisers can compare and contrast results, put together multiple lists to work through, and broaden horizons to new potential projects and donor segments.

“We pride ourselves in providing innovations quickly that will have an impact on your organization even more rapidly. We knew our clients needed something to set them apart and fundraise more effectively. Sometimes, it’s about taking a step back and looking at things differently,” said Mary Cote, VP Product, iWave.

This new feature is part of iWave’s cloud-native platform that boasts a fresh modern design and intuitive layout. The platform is faster, more powerful, and more scalable than before, allowing new enhancements and functionality to be added quickly and easily.

“At iWave, we pride ourselves on being at the forefront of nonprofit fundraising innovation with an agile development process that leverages client and industry insights to continuously bring more value, along with the best customer service in the industry to our nonprofits, higher education, and healthcare organizations," said Ross Beattie, President & CEO, iWave. "We know we’re changing the game with this new
feature and we are excited to see how our clients can succeed and do more for their communities with our help.”

Check out our latest blog post on this exciting new feature here.

About iWave
iWave, the industry’s top-rated fundraising intelligence solution, enables nonprofit organizations to fundraise with confidence. In a new era of nonprofit fundraising, iWave solves critical challenges facing fundraising professionals today: how to identify, qualify and retain donors to raise more major gifts. iWave’s intuitive and easy-to-use solutions give access to the industry’s highest quality wealth and philanthropic information so you can determine who to ask, how much to ask for, and when to ask. Since 1991, over 6000 clients, including many of the largest education, healthcare and nonprofit organizations in the World, have relied on iWave to power their fundraising efforts. Visit our website and blog, follow us on Twitter and LinkedIn and like us on Facebook and Instagram.

Dana Prestigiacomo
iWave
+1 800-655-7729
email us here


Source: EIN Presswire

NovaQuest Private Equity Acquires CoreRx, Inc.

New Strategic Financial Sponsor to Support Continued Growth and Capability Expansion

CLEARWATER, FLORIDA, UNITED STATES, January 19, 2021 /EINPresswire.com/ — NovaQuest Private Equity Acquires CoreRx, Inc.
New Strategic Financial Sponsor to Support Continued Growth and Capability Expansion
For immediate release

NovaQuest Private Equity (“NovaQuest”) today announced its acquisition of CoreRx, Inc., a global contract development and manufacturing organization (“CDMO”).

Based in Clearwater, FL, CoreRx provides clinical and commercial CDMO services to a wide range of small to mid-sized pharmaceutical and biotech clients. Founded in 2006, the Company offers preformulation, formulation, analytical and stability, clinical manufacturing, commercial manufacturing, and packaging services. The Company’s deep development expertise allows it to solve complex formulation challenges. Its small-batch manufacturing capabilities, coupled with a responsive customer mindset, allow CoreRx to be a nimble, hands-on partner for its valued customers.

“This transaction is an endorsement of CoreRx’s success to date and its potential for future growth with NovaQuest, a firm with deep healthcare and life sciences expertise and a long history of partnering with market-leading businesses to take them to the next level,” said Todd R. Daviau, President and CEO of CoreRx. “NovaQuest’s expertise in pharmaceutical services and enabling technologies will be invaluable as we look to further grow and enhance the value of our business in partnership with our customers.”

“Todd and his management team have done an excellent job building CoreRx from the ground up, growing from a small development organization into a high-quality, end-to-end CDMO with proven commercial capabilities,” said Ashton Poole and Jeff Edwards, Partners at NovaQuest. “We look forward to supporting the CoreRx team as they continue to build out their capabilities and provide best-in-class service to the pharmaceutical industry.”
Affiliates of Signet Healthcare Partners will retain a minority position. Deal terms were not announced.

Goldman Sachs Specialty Lending Group provided debt financing for the transaction. William Blair & Company served as exclusive financial advisor to CoreRx. Sheppard Mullin and Johnson Pope served as legal advisors to CoreRx, and Smith Anderson served as legal advisor to NovaQuest.

About CoreRx:
CoreRx is a CDMO with full-service capabilities to support clinical through commercial manufacturing, offering state of the art facilities to support your supply chain needs. Our integrated offerings provide comprehensive services for the development, manufacturing, and testing of solid, liquid, and semi-solid dosage forms. For more information, please visit www.corerxpharma.com.

About NovaQuest Private Equity:
NovaQuest Private Equity is a leading investor in technology and services companies in the life sciences and healthcare sectors. NovaQuest was formed in 2000 with the vision of building an investment platform to provide strategic capital and operational leverage in partnership with strong management teams. The investment team consists of highly seasoned operational and investment professionals with significant investment experience and deep life science and healthcare expertise. Furthermore, NovaQuest benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing, and growing NovaQuest portfolio companies and investments. For more information, please visit www.novaquest.com.

###

Mark DaFonseca
CoreRx, Inc.
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

North Carolina US Navy Veterans Lung Cancer Advocate Has Endorsed the Lawyers at Karst von Oiste to Assist a Navy Veteran with Lung Cancer-Who Also Had Asbestos Exposure-Compensation May Exceed $100,000

North Carolina

"If you are a Navy Veteran with lung cancer and you had exposure to asbestos in the navy please call the lawyers at the law firm of Karst von Oiste about what might be significant compensation. ”

— North Carolina US Navy Veterans Lung Cancer Advocate

CHARLOTTE , NORTH CAROLINA, USA, January 19, 2021 /EINPresswire.com/ — The North Carolina US Navy Veterans Lung Cancer Advocate says, "If you are a Navy Veteran with recently diagnosed lung cancer and you had heavy exposure to asbestos while serving in the navy please call the lawyers at the law firm of Karst von Oiste at 800-714-0303 about what might be significant financial compensation. In some to many instances-financial compensation for a person like this might exceed $100,000 and the claim does not involve suing the navy. The person we are trying to identify is over 60 years old and their asbestos exposure occurred on a navy ship, submarine or at a shipyard in the 1960s or 1970s. It does not matter if this person smoked cigarettes.

"If your husband or dad is a Navy Veteran has just been diagnosed with lung cancer and you know he had significant exposure to asbestos in the navy prior to 1982 please call the lawyers at the law firm of Karst von Oiste anytime at 800-714-0303 to discuss compensation. Most people like this do not realize the $30 billion dollar-asbestos trust funds were set up for them too. You have nothing to lose by calling the lawyers at Karst von Oiste if the person we have described is you or your loved one." www.karstvonoiste.com/

The North Carolina US Navy Veterans Lung Cancer Advocate’s free services are available to people with asbestos exposure lung cancer or mesothelioma in Charlotte, Raleigh, Greensboro, Winston-Salem, Fayetteville, Asheville, Wilmington or anywhere in North Carolina. https://NorthCarolina.USNavyLungCancer.Com

High-risk work groups for exposure to asbestos in North Carolina include Veterans of the US Navy, civilian workers at Fort Bragg, a worker at one of North Carolina’s dozens of power plants, steel mill workers, pulp, or paper mill workers, public utility workers, factory workers, plumbers, welders, insulators, millwrights, electricians, coal miners, auto mechanics, machinists, and construction workers. Typically, the exposure to asbestos occurred in the 1950’s, 1960’s, 1970’s, or 1980’s. www.karstvonoiste.com/

According to the American Cancer Society for nonsmokers who have been exposed to asbestos in their workplace the risk of lung cancer is five times that of unexposed workers. https://www.cdc.gov/cancer/lung/statistics/index.htm.

The US Navy Veterans Lung Cancer Advocate says, “If your husband, dad, coworker or neighbor has just been diagnosed with lung cancer and you know they had significant exposure to asbestos in the navy, at a shipyard or while working at a factory, at power plant, public utility, or as a plumber, electrician welder, mechanic or any kind of skilled trades group in any state please have them call us anytime at 800-714-0303. Most people like this never get compensated-even though the asbestos trust funds were set up for them too. We are trying to change this sad fact.” https://USNavyLungCancer.Com

States with the highest incidence of lung cancer include Kentucky, West Virginia, Maine, Tennessee, Mississippi, Ohio, Indiana, Louisiana, Arkansas, Missouri, North Carolina, Rhode Island, Alabama, and Delaware. www.karstvonoiste.com/

For more information about asbestos exposure please visit the NIH’s website on this topic: https://www.cancer.gov/about-cancer/causes-prevention/risk/ substances/asbestos/asbestos-fact-sheet.

Michael Thomas
North Carolina US Navy Veterans Lung Cancer Advocate
+1 800-714-0303
email us here


Source: EIN Presswire

Masina Hospital with ReLiva Physiotherapy & Rehab Offers Comprehensive Post COVID Rehab

Recovery post Covid 19 with RespiRehab Pulmonary Rehab program by ReLiva Physiotherapy

Recovery post Covid 19 with RespiRehab Pulmonary Rehab program by ReLiva Physiotherapy

Recover from Covid symptoms like breathlessness, fatigue, cough and weakness with RespiRehab Pulmonary Rehab

Recover from Covid symptoms with RespiRehab Pulmonary Rehab

Personalised Pulmonary Rehab with Respiratory therapists from Reliva Physiotherapy

Personalised Pulmonary Rehab with Respiratory therapists from Reliva Physiotherapy

Masina Hospital offers affordable post COVID rehab with ReLiva Physiotherapy – Respirehab to improve breathing & lung function; ease body pain and fatigue.

At ReLiva, we believe that every patient deserves a complete recovery. We want to assist people to put COVID-19 behind and get their lives back.”

— Subodh Gupta, Founder and CEO of ReLiva Physiotherapy & Rehab

MUMBAI, MAHARASHTRA, INDIA, January 19, 2021 /EINPresswire.com/ — For many COVID-19 patients, the battle to breathe well continues well after the discharge from hospital. Many of the patients who develop moderate to severe symptoms of COVID-19 will require rehabilitation after they are discharged or risk developing chronic lung issues that can significantly impair their quality of life and ability to return to work.

Masina Hospital a leading private charitable trust hospital, now offers affordable and comprehensive post COVID rehabilitation in partnership with ReLiva Physiotherapy & Rehab (Respirehab Pulmonary Rehabilitation Program). The post COVID rehab program has been designed in accordance with evidence based international guidelines and is supervised by Cardiorespiratory physiotherapists. Respirehab focuses not only to improve breathing capacity and lung function, it also assists patients with other long covid symptoms such as musculoskeletal pain, fatigue and vertigo.

For patients who are unable to visit the clinic, Respirehab is also available through tele-physiotherapy at www.respirehab.com. Respirehab has successfully assisted many patients in their fight with breathlessness and fatigue post COVID. A study published in Indian Journal of Physiotherapy & Occupational Therapy showed an average 71% improvement in respiratory function (measured by SGRQ) and almost 100% improvement in exercise capacity (measured by 1 RM-10RM) for patients after 1-month Respirehab program.

Speaking about Respirehab Pulmonary Rehabilitation Program, Dr Sonam Solanki, Consultant Pulmonologist, said: "A guided and supervised pulmonary rehabilitation makes a significant difference to well-being of the patients. It is important for patients to undergo the rehabilitation to ensure complete recovery."

Subodh Gupta, Founder and CEO of ReLiva Physiotherapy & Rehab says “At ReLiva, we believe that every patient deserves a complete recovery. We want to assist people to put COVID-19 behind and get their lives back.”

Know More about Post Covid Rehab with Respirehab at : https://respirehab.com/covid-19/

Watch a Patient Recovery feedback video: Covid Patient talks about post corona experience with Respirehab at https://youtu.be/XmRDkqW0Ptw

Here is another Patient Feedback for recovery with Respirehab : https://g.co/kgs/QWDkWx

About Respirehab Pulmonary Rehabilitation Program:
Respirehab is a comprehensive pulmonary rehab offering from ReLiva Physiotherapy & Rehab, India’s leading Physiotherapy organization. Post Covid Respirehab programme has been developed by cardio respiratory physiotherapists and is being delivered in person at Masina Hospital and also digitally for patients at home. For more information, please visit https://respirehab.com

About Masina Hospital:
Masina Hospital Trust is first and oldest healthcare setup in Mumbai with an illustrious history and goodwill spanning generations. The hospital is run with primary, secondary and tertiary care solutions with an emphasis on holistic service in a safe and clean environment, emphasizing on eco-friendly practices. The hospital works for all sections of the society without any bias or discrimination related to gender, community, caste or socio-economic status.

Vaishali Gupta
ReLiva Physiotherapy & Rehab
+91 99209 91584
contact@reliva.in

Patient Recovery feedback with Post Covid Respirehab Pulmonary Rehabilitation Program from ReLiva Physiotherapy


Source: EIN Presswire

New Hampshire Mesothelioma Victims Center Appeals to the Family of a Navy Veteran with Mesothelioma in New Hampshire to Call Attorney Erik Karst of Karst von Oiste About Expedited Compensation

"Rather than ordering anything 'free' on the Internet when it comes to mesothelioma compensation-please call attorney Erik Karst of Karst von Oiste at 800-714-0303. Erik Karst is amazing.”

— New Hampshire Mesothelioma Victims Center

MANCHESTER , NEW HAMPSHIRE, USA, January 19, 2021 /EINPresswire.com/ — The New Hampshire Mesothelioma Victims Center is appealing to the wife or adult son-daughter of a Navy Veteran who has just been diagnosed with mesothelioma in New Hampshire to get serious about financial compensation and to call attorney Erik Karst of the law firm of Karst von Oiste about what could be significant financial compensation-that might exceed a million dollars. In some instances-Erik Karst and his amazing team at Karst von Oiste can expedite financial compensation. If a person with mesothelioma in New Hampshire is serious about compensation it is vital they hire a lawyer that knows what they are doing. For direct access to attorney Erik Karst of the law firm of Karst von Oiste please call 800-714-0303-anytime. www.karstvonoiste.com/

The group says, "We are warning a family of an individual with mesothelioma to steer clear of online 'freebies' offering kits, guides, booklets, calculators, five minute compensation tests-because all these 'free' things are intended to do is identify people with mesothelioma-and then the sponsor lawyers hound them night and day. Rather than ordering anything 'free' on the Internet when it comes to mesothelioma compensation-please call attorney Erik Karst of Karst von Oiste at 800-714-0303. He is an amazing resource, and he knows what he is talking about." www.karstvonoiste.com/

The New Hampshire Mesothelioma Victims Center’s free services are available to a person with mesothelioma anywhere in New Hampshire including communities such as Manchester, Nashua, Concord, Dover, Rochester, Keene, Derry, or Portsmouth. www.karstvonoiste.com/

For the best possible treatment options in New Hampshire we strongly recommend the following heath care facility with the offer to help a diagnosed victim, or their family get to the right physicians at this hospital. Norris Cotton Cancer Center: https://cancer.dartmouth.edu

High risk occupations for asbestos exposure in New Hampshire include the US Navy, shipyard workers, manufacturing workers, electricians, welders, plumbers, machinists, mechanics, power plant workers, paper mill workers, auto/truck brake technicians and construction workers.
http://NewHampshire.MesotheliomaVictimsCenter.Com

For more information about mesothelioma please refer to the National Institutes of Health’s web site related to this rare form of cancer: https://www.cancer.gov/types/mesothelioma

Michael Thomas
New Hampshire Mesothelioma Victims Center
+1 800-714-0303
email us here


Source: EIN Presswire

Social Assistance Market Employs Big Data Analytics To Gather Insights For Social Services

Social Assistance Market Report 2021: COVID-19 Impact And Recovery To 2030

Social Assistance Global Market Report 2021: COVID-19 Impact And Recovery To 2030

The Business Research Company’s Social Assistance Global Market Report 2021: COVID-19 Impact and Recovery to 2030

LONDON, GREATER LONDON, UK, January 19, 2021 /EINPresswire.com/ — New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

Social assistance providers are increasingly using data-driven approaches such as big data and predictive analytics to gather insights related to social assistance services. Predictive analytics involves the use of data, statistical algorithms and machine learning techniques to identify the likelihood of future outcomes based on historical data. Big data analytics involves extracting hidden patterns and useful information from a large set of data. These techniques help in reporting, detecting, or correcting a non-compliance while monitoring target population. In the social services industry overview for example, Hillside Family of Agencies, a human services provider for youth and families, is using predictive analytics to reduce the dropout rates among youth in high school. Good Samaritan Society, a non-profit provider of senior care and services, has partnered with IBM to use big data and analytics software for its clinical and operational data about the patients.

The global social assistance market is expected to grow from $1.28 trillion in 2020 to $1.43 trillion in 2021 at a compound annual growth rate (CAGR) of 11.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. As per social assistance industry analysis, the healthcare and social assistance market is expected to reach $1.95 trillion in 2025 at a CAGR of 8%.

Here Is A List Of Similar Reports By The Business Research Company:

Social Services Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/social-services-global-market-report-2020-30-covid-19-impact-and-recovery

Community And Individual Services Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/community-and-individual-services-global-market-report-2020-30-covid-19-impact-and-recovery

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Squarex Announces End of Phase 2 Meeting with FDA for its Cold Sore Prevention Asset

Typical cold sore infection caused by Herpes simplex virus

Image of the Herpes simplex virus, or herpes labialis, which causes cold sores

Squarex Pharma announced updated results from its successful Phase 2 clinical study on humans with its novel asset SQX770 for prevention of cold sores.

We believe our novel drug SQX770 addresses a large, global unmet clinical need for those people suffering from frequent cold sores due to herpes labialis. This is a $600 million market in the USA.”

— Hugh McTavish

ST PAUL, MINNESOTA, USA, January 19, 2021 /EINPresswire.com/ — Squarex Pharma (SQX), a St. Paul, Minnesota, USA-based company, announced updated results from its Phase 2 clinical study on humans with its novel asset SQX770 for prevention of cold sores, also known as herpes labialis or oral herpes, an illness caused by herpes simplex virus, usually type 1 (HSV-1).

SQX770 is a unique, first in class topical immunomodulator. SQX770 is the only product shown to reduce the number of cold sore events or flareups as well as their severity.

About 50% of the Western population is infected with HSV-1. Herpes outbreaks give rise to cold sores, usually seen as painful sores or blisters around the lips of the patient. Currently there are no preventative treatments, only pills, creams, and ointments to be used once cold sores appear in order to shorten the outbreak. Current drugs do nothing to prevent reoccurrence of outbreaks or reduce the number of outbreaks.

SQX770 addresses a very substantial worldwide market—2.1% of the population has 6 or more outbreaks per year and 15% have 1 or more.

SQX770 is applied topically and has a systemic effect: one topical dose applied with a dermal patch to the upper arm prevents outbreaks for three months. An earlier Phase 1 study at Massachusetts General Hospital in Boston, USA, showed that SQX770 has significant efficacy versus placebo in reducing the recurrence of cold sores.

SQX770 is thought to work by stimulating the sufferer’s immune system via the dendritic cell network in the skin and stimulation of T-cell activity. SQX770 is intended to be available by a doctor’s prescription although ultimately it could be available over the counter in pharmacies.

The Phase 2 study with 139 patients using SQX770 at 5 sites confirmed this in showing reduced number of cold sore outbreaks and further showed reduction in severity of the (fewer) outbreaks that occurred.

Thus, efficacy and safety have been demonstrated in each of two double-blind placebo-controlled clinical trials. A third clinical trial showed significant improvement in cellular immune response to the HSV-1 virus after dosing with SQX770.

Patents covering SQX770 are issued in US, Europe, and Japan until at least 2036 and pending in China, Canada, India, and Australia

Squarex announces that is has completed an End-of-Phase 2 meeting with the U.S. FDA which has provided a clear and achievable path to a New Drug Application in the USA following ultimately a routine Phase 3 study. It will pursue a similar path for regulatory approval in Europe and the rest of the world.

Squarex seeks a global strategic partner with which it can collaborate to exploit its SQX770 drug and take it through final clinical development to market authorisation.

Hugh McTavish, CEO of Squarex, said “Results from patients recruited into our clinical study are very promising; we believe that our novel drug asset SQX770 addresses a large, global unmet clinical need for those people suffering from frequent cold sores due to herpes labialis. Our end of Phase 2 meeting with FDA has been very positive and helpful in pointing the way forward for marketing approval for SQX770. We estimate that the annual market for prevention of oral herpes in the USA is about $600 million.”

For more information about Squarex and partnering opportunities for its Herpes Labialis preventative treatment, please contact:
Dr. Bill Mason
The Sage Group
The Old Black Barns
Lord’s Lane, Ousden CB8 8TX UK
Tel: +44 (0) 7785 950134
wtm@sagehealthcare.com
Or
Wayne Pambianchi
The Sage Group Inc.
1802 Route 31 North
#381 Clinton
New Jersey 08809 USA
Phone: +1 908 2306170
wpambianchi@sagehealthcare.com
Or
Hugh McTavish
CEO, Squarex Pharma LLC
Tel: +1 651 4920283
hmctavish@squarex-pharma.com
About Squarex Pharma
Squarex is a clinical stage pharmaceutical company which has developed a topical formulation of the immunomodulator squaric acid dibutyl ester for the prevention of recurrent cold sores (herpes labialis) and other infections caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2.

More than 6 Million people in the U.S. alone suffer with 6 or more herpes labialis outbreaks every year with no existing medications indicated for the prevention of outbreaks.

Squarex’s drug SQX770 is unique. A single topical application to the arm, not the lip or face, has been shown in clinical trials to prevent cold sore outbreaks (oral herpes) in people with frequent outbreaks for 3 months.

Website: https://squarex-pharma.com/

About The Sage Group, Inc.

The Sage Group Inc. is a leader in the provision of strategic and transactional advice to health care companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields. Sage currently maintains offices in USA, Europe, Israel and Japan. Since its founding in 1994, The Sage Group has served more than 200 clients in the US, Europe and Asia, and completed numerous transactions including divestitures, alliances, acquisitions and financings with values ranging from $5 million to $500 million.

The Sage Group is an organization of experienced and successful executives who are committed to the service of the very vital and dynamic health care industry and its investors.

The range of services offered includes:
• Strategic alliances and licensing/partnering
• M&A, divestment, buy- and sell- side
• Global product and technology acquisition searches
• Strategic assessment and planning
• Due diligence, technology and molecule assessment, valuation
• New ventures, interim management
• Facilitating investment in R&D and/or company equity through introductions, network and brokering

The Sage Group's Principals, each an Executive Director, have been Founders, Chairmen, Presidents, CEO's and COO's of a number of emerging health care companies. These Principals have also held senior level management positions in large multi-national organizations. In addition to their management backgrounds, The Sage Group's Principals also have extensive experience in providing professional management consulting services to healthcare industry clients. All these experiences are being applied by The Sage Group to assist industry participants in these challenging times.
Website: www.sagehealthcare.com

Dr. Bill Mason
The Sage Group
+44 7785950134
wtm@sagehealthcare.com


Source: EIN Presswire

Optibrium Enhances Compound Design Strategies in Major Upgrade to StarDrop Software

Optibrium Enters Cheminformatics Collaboration with MSD

Optibrium Enters Cheminformatics Collaboration with MSD

New features include reaction-based library enumeration for novel molecule generation and optimisation, and seamless AI-integration for deeper data analysis

CAMBRIDGE, CAMBRIDGESHIRE, UNITED KINGDOM, January 19, 2021 /EINPresswire.com/ — Optibrium™, a developer of software for drug discovery, today announced the release of the newest version of StarDrop™, a comprehensive software platform for small molecule design, optimisation and data analysis. The new release, StarDrop 7.0, further extends the software’s compound design strategies, provides enhanced workflows, and seamlessly connects with Optibrium’s Cerella™ platform, delivering unique Artificial Intelligence (AI) capabilities to drug discovery scientists. More than 150 organisations worldwide use StarDrop in their research programs – the new features have been developed in close collaboration with key customers and have proven their benefits in identifying optimally balanced, successful and novel compounds faster.

Reaction-based Library Enumeration (RBE) enables chemists to easily enumerate compound libraries and explore optimisation strategies. As a new feature of StarDrop 7.0, RBE delivers a highly-flexible and user-friendly environment to generate new molecules, by applying tractable, robust chemical reactions and linking directly with in-house and commercial building block libraries. Combined with StarDrop’s multi-parameter optimisation capabilities, this enables medicinal chemists to target high-quality and synthetically accessible compounds.

StarDrop 7.0 seamlessly integrates with Cerella, Optibrium’s newly introduced AI software platform, providing intuitive workflows that leverage Cerella’s unique capabilities to accelerate discovery cycles and reduce costs while targeting high-quality compounds. Deploying advanced deep learning methods, Cerella has been demonstrated to extract additional value from compound data, highlighting relationships between structures, activities and other properties on a scale and accuracy unmatched by conventional cheminformatics methods.

Edmund Champness, Optibrium’s Chief Scientific Officer, commented, “Having surveyed the available reaction-based enumeration tools, and found no solutions that met their requirements, our collaborators asked us to develop this feature. We thank them for their input, which was instrumental in shaping an industry-leading capability with the elegance and functionality they’ve come to expect from StarDrop. Added to which, after the successful launch of our AI platform Cerella, we are excited to provide our users with seamless access to a groundbreaking AI system through its integration in StarDrop 7.0.”

For further information on Optibrium, StarDrop 7.0 or Cerella, please visit www.optibrium.com, contact info@optibrium.com or call +44 1223 815900.

Sarah Jeffery
Optibrium
+44 7771 730919
email us here
Visit us on social media:
Twitter
LinkedIn


Source: EIN Presswire

Full-Arch Dental Implants from Castle Dental Convenient Alternative to Dentures

Logo for Center Valley dentist

Center Valley dentists at Castle Dental providing dental implants

Dental implants help replace missing teeth and stabilize dentures on the upper and lower arch.

CENTER VALLEY, PA, UNITED STATES, January 19, 2021 /EINPresswire.com/ — Castle Dental in Center Valley is offering full-arch dental implants. While dentures may grow loose over time, removable full-arch dental implants are a convenient alternative.

When multiple teeth are missing, a full-arch denture can be attached to implants placed in the upper or lower jaw. This stabilizes the denture to keep it from slipping or sliding and also allows for the denture to be removed.

“A removable restoration using dental implants is more hygienic and more cost-effective,” explains Dr. Matthew Lang, dentist in Center Valley.

Fixed full-arch restorations are also offered using six to eight implants. However, if a patient is only missing one or two teeth, a single dental implant is suggested instead.

Dental implants in Center Valley remain one of Castle Dental’s most popular treatment options. An abutment and crown give them a natural look and feel and they boast a success rate well over 90%, with supplemental procedures available to help aid in healing.

In addition to dental implants, Castle Dental also offers crowns, veneers, and general dentistry. To learn more, request an appointment with the Lehigh Valley dentist by visiting https://castledentalcare.com/appointment-request/.

About Castle Dental: Castle Dental is a leading provider of cosmetic dentistry and dental implants in Center Valley, PA. Doctors Matthew Lang and Andrew Branton offer patients high-quality, experienced, and comfortable care. Sedation dentistry, dental crowns, and general dentistry are also available. To learn more visit https://www.castledentalcare.com.

Melissa Dugan
Castle Dental
+1 6102822249
email us here
Visit us on social media:
Facebook


Source: EIN Presswire